Comments on: Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent or Metastatic HNSCC

Comments on: Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent or Metastatic HNSCC https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/ipilimumab-nivolumab-hnscc-head-neck-cancer-no-clinical-benefit/ Sat, 14 Oct 2023 02:30:34 +0000 hourly 1 https://wordpress.org/?v=6.4.3